KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Common Equity (2017 - 2025)

Novartis Ag (NVS) has disclosed Common Equity for 9 consecutive years, with $46.5 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 5.68% to $46.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 billion through Dec 2025, up 5.68% year-over-year, with the annual reading at $46.5 billion for FY2025, 5.68% up from the prior year.
  • Common Equity hit $46.5 billion in Q4 2025 for Novartis Ag, up from $44.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $67.8 billion in Q4 2021 to a low of $44.0 billion in Q4 2024.
  • Historically, Common Equity has averaged $52.9 billion across 5 years, with a median of $46.8 billion in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 4879.56% in 2021 and later decreased 21.33% in 2023.
  • Year by year, Common Equity stood at $67.8 billion in 2021, then fell by 12.38% to $59.4 billion in 2022, then dropped by 21.33% to $46.8 billion in 2023, then decreased by 5.78% to $44.0 billion in 2024, then increased by 5.68% to $46.5 billion in 2025.
  • Business Quant data shows Common Equity for NVS at $46.5 billion in Q4 2025, $44.0 billion in Q4 2024, and $46.8 billion in Q4 2023.